Inactivation of infectious pathogens in labile blood components: meeting the challenge.
about
Chagas disease and transfusion medicine: a perspective from non-endemic countriesImplementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets.Tick-borne diseases in transfusion medicine.Pathogen inactivation technology: cleansing the blood supply.Viral inactivation in hemotherapy: systematic review on inactivators with action on nucleic acidsRed blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.Influence of blood prestorage conditions and white blood cell filtration on the bacterial load of blood deliberately inoculated with Gram-positive and Gram-negative pathogens.Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver.Application of controlled hypotension combined with autotransfusion in spinal orthomorphiaPolymerase chain reaction inhibition assay documenting the amotosalen-based photochemical pathogen inactivation process of platelet concentrates.The efficacy of photochemical treatment with methylene blue and light for the reduction of Trypanosoma cruzi in infected plasma.Stored red blood cell viability is maintained after treatment with a second-generation S-303 pathogen inactivation process.The efficacy of photochemical treatment with amotosalen HCl and ultraviolet A (INTERCEPT) for inactivation of Trypanosoma cruzi in pooled buffy-coat platelets.
P2860
Q26777968-40CE088F-7A0D-41CB-9ABC-5424BAF0FDA8Q33448189-419F9593-B5A7-45A9-BA0C-62743DDC8F3DQ34619674-6ED61AD7-9D07-4EA2-9ECF-E51A36D26A21Q36044573-7C49CC87-737B-4BF9-8053-9464F7FBC423Q38050757-B244537A-9A3F-4607-B59E-FBBF8C848EE9Q40324501-8233CDA4-E0AE-4A41-AD5D-DBD8ABE8AB1FQ41460448-52F37FD8-CF7A-4BAE-9266-666EE034A07FQ41786777-1FBA8884-2909-49EC-A810-4FA8FDEE46E1Q42123210-85304294-FCC2-4BD3-AD7F-AC8D5AC1493EQ45303414-A9701641-009E-4B52-9F73-AD0FF1D04CF4Q50474223-180FB303-BA7D-4B4B-B107-FB56E77BD7B4Q50536784-12BCC970-7362-4085-B394-0DA05D746BCFQ50704130-019746DC-E48E-4B20-A120-798C08C2BC79
P2860
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@ast
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@en
type
label
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@ast
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@en
prefLabel
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@ast
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@en
P1476
Inactivation of infectious pathogens in labile blood components: meeting the challenge.
@en
P2093
P304
P356
10.1016/S1246-7820(01)00117-3
P577
2001-06-01T00:00:00Z